An insulin syringe aids in delivering insulin to diabetic patients in required doses. The insulin syringes consist of three parts-a needle, a barrel, and a plunger, and is available in various sizes. The size of the insulin syringe is selected based on the desired dosage of insulin to be administered to diabetic patients. The major factors that fuel the growth of the market are the rising aging population and increasing number of diabetic patients globally. In addition, increasing incidence of obesity and people adopting an unhealthy lifestyle supplement the market growth. However, high costs of advanced insulin syringes restrain the growth of the insulin syringe market.
The report segments the market on the basis of end users and region. Based on end user, the market is divided into hospital, homecare, and others. Based on region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players profiled in this market are Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company, Biocon Ltd., Ypsomed AG, Wockhardt Ltd., Medtronic Plc, Abbott Laboratories, Animas Corporation, and F. Hoffmann-La Roche, Ltd.
- The study provides an in-depth analysis of the global insulin syringes market, with current trends and future estimations to elucidate imminent investment pockets.
- It presents a quantitative analysis from 2016 to 2023 to enable stakeholders to capitalize on prevailing market opportunities.
- Extensive analysis of the market by type assists in understanding various forms of insulin syringes available.
- Key players have been profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.
Insulin Syringes Market Key Segmentation:
By End User
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA